ASCO GU 2022 | The evolving treatment landscape of advanced and metastatic urothelial carcinoma

Vadim Koshkin, MD, University of California San Francisco, San Francisco, CA, discusses the evolving treatment landscape of advanced and metastatic urothelial carcinoma (mUC). Immune checkpoint inhibitors have become the cornerstone for mUC over the last five years following the approval of atezolizumab in 2016, with subsequent approval of pembrolizumab, nivolumab, enfortumab vedotin, cetuximab and sacituzumab govitecan, as well as FGFR-targeted agents such as erdafitinib. Patients who progress on immune checkpoint inhibitors are likely to receive one of these targeted agents. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.